FDMT 4D Molecular Therapeutics, Inc.

NASDAQ
$10.79

4D Molecular Therapeutics, Inc. (FDMT) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $1.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -7.1% since its last earnings release on November 12, 2026.

4D Molecular Therapeutics Missed Consensus Estimates
Thursday, November 12, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($1.10)
Rev est $3.92M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $11.43

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About 4D Molecular Therapeutics, Inc.

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.